MedTrace Logo

Fulvestrant 500mg in Patients With Advanced Breast Cancer

NCT02909361 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-04-20

No results posted yet for this study

Summary

Fulvestrant 500mg in Patients With Advanced Breast Cancer

Conditions

Interventions

DRUG

Fulvestrant

500 mg on days 0, 14, and 28, and every 28 days thereafter

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xichun Hu, MD, PhD · Fudan University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-11
Primary Completion
2022-06-30
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02909361 on ClinicalTrials.gov